Silexion Therapeutics Corp
SLXN· Nasdaq
SLXNSilexion Therapeutics Corp
Filed Aug 29, 2024 · 10-Q · 60 days after period end · 0001213900-24-073934
| Metric | Q2 2024 | Q2 2023 |
|---|---|---|
| Net Income | -$1.49M | -$1.88M |
| EPS Diluted | $197.80 | $6.54 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Silexion Therapeutics Corp · CIK 2022416 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 29, 2024 · 60 d after period end
